With the semaglutide patent in India set to expire soon, drugmakers Zydus Lifesciences and Lupin have signed a licensing and supply deal on Tuesday (17) to comarket semaglutide injections, with a reusable pen device, in the country
This alternative would be more convenient for patients and eliminate the need for refrigeration
DSIP is not a substitute for healthy sleep hygiene addressing sleep environment, limiting caffeine/blue light, managing stress, and maintaining a stable schedule are still foundational
doi: 10.1080/17450390512331342368, 142
Mol Med 2022;28:11
In the 68-week STEP 1 trial, adults receiving once-weekly semaglutide 2.4 mg lost an average of 14.9% of their starting body weight, compared with 2.4% among participants receiving placebo